The group's principal activity is to research and develop drugs for the treatment of immune system disorders and skin diseases. The group's initial product is psoraxine, a protein extract used for the treatment of the skin disease psoriasis. Psoraxine is a synthesized immuno-therapeutic agent, presented in liquid form and is packed in 0.5 mg ampules for intra-muscular injection. The group's second product is for the treatment of leishmaniasis. The group is a development stage company.
